A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor.
Roberto CaporaliAditi KadakiaOliver HowellJayesh PatelJack MilliganSander StrengholtSophie BarlowPeter C TaylorPublished in: Advances in therapy (2024)
Patients who switched from TNFi to UPA had significantly better clinical outcomes of remission, no pain, and complete adherence than those who cycled TNFi or switched to another MOA.